Edgewise Therapeutics, Inc. announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The conference will take place in Atlanta, GA at the Georgia World Congress Center from April 6-8, 2024.

Edgewise Presentation at ACC.24: Session: From the bench to the bedside: Advances in heart failure & cardiomyopathies; Poster Presentation: 1087-05 - Chronic Treatment with the Novel Sarcomere Modulator EDG-7500 Improves Left Ventricular Distensibility and Cardiac Output Recruitment Under Stress in a Mini-pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy; Presenter: Marc Evanchik, Vice President Discovery and Translational Pharmacology, Edgewise Therapeutics; Date: April 7, 2024, 3:15 ? 3:25 pm ET.